Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2007 June;48(3) > The Journal of Cardiovascular Surgery 2007 June;48(3):323-31

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

ORIGINAL ARTICLES  CARDIAC SECTIONFREEfree


The Journal of Cardiovascular Surgery 2007 June;48(3):323-31

Copyright © 2007 EDIZIONI MINERVA MEDICA

language: English

Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery: a phase 3, randomized, double-blind clinical study

Lowe J., Luber J., Levitsky S., Hantak E., Montgomery J., Schiestl N., Schofield N., Marra S.

1 Duke University Medical Center Durham, NC, USA 2 Franciscan Health System Research Center Tacoma, WA, USA 3 Department of Surgery Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA 4 Baxter AG Vienna, Austria 5 Baxter Healthcare Corporation Westlake Village, CA, USA 6 UMDNJ Robert Wood Johnson Camden, NJ, USA


FULL TEXT  


Aim. TISSEEL VH is the only commercially available fibrin sealant indicated as an adjunct to conventional methods of hemostasis during cardiac surgery. A next generation fibrin sealant (TISSEEL VH S/D) has been developed in frozen, ready-to-use form with an added virus inactivation step (solvent/detergent [S/D] treatment) to provide added safety and convenience to the currently licensed product. This study was performed to compare efficacy and safety of the two products.
Methods. Phase 3, prospective, randomized, double-blind, multicenter study to compare TISSEEL VH S/D to TISSEEL VH during cardiac surgery. The primary efficacy endpoint was the proportion of patients who achieved hemostasis at the primary treatment site within 5 min, and maintained hemostasis until surgical closure.
Results. The proportion of patients who achieved hemostasis at the primary treatment site within 5 min, and maintained hemostasis until surgical closure was 88.2% for TISSEEL VH S/D and 89.6% for TISSEEL VH in the intent-to-treat population. The difference in proportions, TISSEEL VH S/D minus TISSEEL VH, was –1.4% with a standard error of 3.70%. The lower 97.5% confidence bound of this difference was –8.6%, which is above the predefined noninferiority margin of 15%. Therefore, TISSEEL VH S/D is at least as efficacious as TISSEEL VH. The safety profile of TISSEEL VH S/D was very similar to that of currently licensed TISSEEL VH as assessed by the safety endpoints.
Conclusion. TISSEEL VH S/D is safe and effective for use as an adjunct to hemostasis in patients undergoing cardiac surgery.

top of page

Publication History

Cite this article as

Corresponding author e-mail